Back ground: Breast cancer radiotherapy plays an important role and can reduce local and regional recurrence, however may be complicated by radiation pneumonitis, the early stage occurs one to three months after treatment characterized mainly by ground glass opacities and consolidate-ion related to radiation portal. The late phase develops six months after the completion of radiation therapy and can progress for as long as two years manifested by atelectactic bands bronchiectasis and lung fibrosis. MDCT has an important role in assessment of lung and pleural changes with grading of these changes.
Aim of the work: To show the role of MDCT in assessment of pleuropneumonic changes after breast cancer radiotherapy.
Patients and methods: This study included 25 breast cancer patients managed with chemotherapy and surgery followed by RT (January 2017 and April 2020).
Results: The study showed that lung and pleural changes varies from no changes to lung consolidation, fibrosis, bronchiectasis and pleural effusion and thickening which affected by different factors.
Conclusion: MDCT has an important role in assessment of early and late lung changes after breast cancer radiotherapy.